23 May 2013
Keywords: dosing, begins, ph, iii, hematide, study, biopharmaceutical
Article | 22 October 2007
US biopharmaceutical firm Affymax and Japanese drug maker Takeda say that dosing has begun in a Phase III clinical trial ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 October 2007
29 October 2007
22 May 2013
© 2013 thepharmaletter.com